Clinical trial · Observational
Responses to COVID-19 Vaccination in Patients With Cancer
Mapping the Responses to COVID-19 Vaccination in Patients With Cancer - the ReCOVer Study
NCT04745377CI-TRIAL-00060375ReCOVercompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is an observational study that will prospectively record and monitor responses and clinical outcomes of patients with cancer after covid-19 vaccination, including measurements of antibody titers in serum and also record potential factors that affect immunity, such as type and stage of cancer, type and time of systemic therapy in relation to covid-19 vaccination.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| IgG neutralising antibody titers to S1 and S2 proteins of SARS-COV-2 virus | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Control Group
- description
- Healthy volunteers from hospital personnel vaccinated for covid-19, who sign informed consent for recording of outcomes and monitor of antibody titers in 3 timepoints
- interventionNames
- Diagnostic Test: IgG neutralising antibody titers to S1 and S2 proteins of SARS-COV-2 virus
- label
- Cancer patients
- description
- Cancer patients with solid tumours, with active disease and/or undergoing active systemic treatment, who will be vaccinated for covid-19
- interventionNames
- Diagnostic Test: IgG neutralising antibody titers to S1 and S2 proteins of SARS-COV-2 virus
Primary outcomes (3)
- measure
- Clinical outcome post vaccination
- timeFrame
- 12 months
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with solid tumours and potentially immunocompromised, ie. currently with active disease and/or undergoing active antineoplastic therapy of any type (chemotherapy, immunotherapy, biologic therapy, targeted therapy) that will be vaccinated for covid-19 within the National Program of Vaccination * patients must sign informed consent for their data monitoring and also for serum antibody titers to covid-19 vaccination measured in three timepoints, prior to 1st dose and 1 and 3 months post completion of two doses Exclusion Criteria: * patients with haematological malignancies are excluded * patients with prior diagnosis of cancer and now on follow-up without active disease are excluded * patients on adjuvant hormonal therapy are excluded
References
Publications (0)
Data not yet available
No reference posted for this study.